asurgeryАмбулаторная хирургияAmbulatornaya khirurgiya = Ambulatory Surgery (Russia)2712-87412782-2591ООО «ГРУППА РЕМЕДИУМ»asurgery-142Research ArticleГНОЙНЫЕ И ТРОФИЧЕСКИЕ ПОРАЖЕНИЯPURULENT AND TROPHIC LESIONSТедизолид – новый антибиотик для решения старых проблем: перспективы применения для лечения осложненных инфекций кожи и мягких тканейTedizolid – a new antibiotic to solve old problems: prospects for the treatment of complicated skin and soft tissue infectionsРодинА. В.RodinA. V.

Родин Антон Викторович – кандидат медицинских наук, доцент кафедры общей хирургии с курсом хирургии факультета дополнительного профессионального образования.

214019, Смоленск, ул. Крупской, д. 28; тел.:+7 (4812) 61-16-28.

Rodin Anton Viktorovich – Candidate of Medical Sciences, Assistant of the Department of General Surgery witha course of surgery at the Faculty of Additional Professional Education.

214018, Smolensk, 28, Gagarin Avenue; tel: +7 (4812) 61–16–28.

rodin.anton.v@gmail.comАгафоновО. И.AgafonovO. I.

Агафонов Олег Игоревич – кандидат медицинских наук, начальник хирургического отделения филиала № 2.

238151, Калининградская  обл., Черняховск, ул. Московская, д. 7; тел.: +7 (911) 856-34–28.

Agafonov Oleg Igorevich – Candidate of Medical Sciences, Head of Surgical Department of the Subdivision No. 2.

238151, Kaliningrad region, Chernyakhovsk, 7, Moskovskaya St.; tel: +7 (911) 856–34–28.

Смоленский государственный медицинский университет Министерства здравоохранения Российской ФедерацииРоссияSmolensk State Medical University of the Ministry of Health of the Russian FederationRussian Federation1409 военно-морской клинический госпиталь Министерства обороны Российской ФедерацииРоссия1409 Naval Clinical Hospital of the Ministry of Defense of the Russian FederationRussian Federation20191204201901-28086Copyright © Родин А.В., Агафонов О.И., 20192019Родин А.В., Агафонов О.И.Rodin A.V., Agafonov O.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.a-surgeon.ru/jour/article/view/142

В работе дана характеристика новому антибиотику из группы оксазолидинонов  – тедизолиду. Результаты проведенных  клинических исследований  показали  высокую эффективность  тедизолида  при осложненных инфекциях кожи и мягких тканей. Применение тедизолида  фосфата сопровождалось  высокой активностью в отношении резистентной к антибиотикам микрофлоры в сочетании с хорошей переносимостью и низкой частотой развития побочных эффектов.

The work describes  a new antibiotic from the oxazolidinone group – tedizolid.  The results  of the clinical studies have shown a high efficacy of tedizolid in complicated  skin and soft tissue infections. The use of tedizolid phosphate was accompanied by high activity against antibiotic-resistant microflora in combination  with good tolerability and low frequency of side effects.

осложненные инфекции кожи и мягких тканейантибактериальная терапияантибиотикорезистентностьтедизолидcomplicated skin and soft tissue infectionsantibiotic therapyantibiotic resistancetedizolidReferencesХирургические инфекции кожи и мягких тканей. Российские национальные рекомендации. Под ред. Б.Р. Гельфанда и др. М.: Издательство МАИ, 2015, 109 с.Surgical skin and soft tissue infections. Russian national recommendations. Edited by B.R. Gelfand et al. M.: MAI Publishing House, 2015, 109 p. (In Russ.)Yamamoto L.G. Treatment of Skin and Soft Tissue Infections. Pediatr Emerg Care. 2017;33 (1):49–55.Yamamoto L.G. Treatment of Skin and Soft Tissue Infections. Pediatr Emerg Care. 2017;33 (1):49–55.Bassetti M., Baguneid M., Bouza E., Dryden M., Nathwani D., Wilcox M. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience withlinezolid. Clin Microbiol Infect. 2014;20 (Suppl 4):3–18.Bassetti M., Baguneid M., Bouza E., Dryden M., Nathwani D., Wilcox M. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience withlinezolid. Clin Microbiol Infect. 2014;20 (Suppl 4):3–18.Сухорукова М.В., Склеенова Е.Ю., Иванчик Н.В., Тимохова А.В., Эйдельштейн М.В., Дехнич А.В. и др. Антибиотикорезистентность нозокомиальных штаммов Staphylococcus aureus в стационарах России: результаты многоцентрового эпидемиологического исследования МАРАФОН в 2011–2012 гг. Клин микробиол антимикроб химиотер. 2014;16 (4):280–286.Sukhorukova M.V., Skleenova E.Yu., Ivanchik N.V., Timokhova A.V., Eidelstein M.V., Dekhnich A.V. et al. Antibiotic resistance of nosocomial strains of Staphylococcus aureus in Russian hospitals: results of a multi-center epidemiological MARAFON study in 2011–2012. Clinical microbiological antimicrobial chemotherapy [Klin. mikrobiol. antimikrob. himioter.]. 2014;16 (4):280–286. (In Russ.)Loewen K., Schreiber Y., Kirlew M., Bocking N., Kelly L. Community-associated methicillin-resistant Staphylococcus aureus infection: Literature review and clinical update. Can Fam Physician. 2017, 63 (7):512–520.Loewen K., Schreiber Y., Kirlew M., Bocking N., Kelly L. Community-associated methicillin-resistant Staphylococcus aureus infection: Literature review and clinical update. Can Fam Physician. 2017, 63 (7):512–520.Решетько О.В., Якимова Ю.Н. Инновационные антибиотики для системного применения. Клин микробиол антимикроб химиотер. 2015;17 (4):272–285.Reshetko O.V., Yakimova Yu.N. Innovative antibiotics for systemic use. Clinical microbiological antimicrobial chemotherapy [Klin. mikrobiol. antimikrob. himioter. 2015;17 (4):272–285.] (In Russ.)Ушкалова Е.А. Тедизолид – препарат нового поколения оксазолидинонов для лечения инфекций кожи и мягких тканей. Фарматека. 2014;15–2:9–12.Ushkalova E.A. Tedizolid is a new generation of oxazolidinones for treatment of skin and soft tissue infections. Pharmacy [Farmateka]. 2014;15–2:9–12. (In Russ.)Zhanel G.G., Love R., Adam H., Golden A., Zelenitsky S., Schweizer F. et al. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs. 2015;75 (3):253–270.Zhanel G.G., Love R., Adam H., Golden A., Zelenitsky S., Schweizer F. et al. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs. 2015;75 (3):253–270.Shaw K.J., Barbachyn M.R. The oxazolidinones: past, present, and future. Ann N Y Acad Sci. 2011;1241:48–70.Shaw K.J., Barbachyn M.R. The oxazolidinones: past, present, and future. Ann N Y Acad Sci. 2011;1241:48–70.Bae S.K., Yang S.H., Shin K.N., Rhee J.K., Yoo M., Lee M.G. Pharmacokinetics of DA-7218, a new oxazolidinone, and its active metabolite, DA-7157, after intravenous and oral administration of DA-7218 and DA-7157 to rats. J Pharm Pharmacol. 2007;59 (7):955–963.Bae S.K., Yang S.H., Shin K.N., Rhee J.K., Yoo M., Lee M.G. Pharmacokinetics of DA-7218, a new oxazolidinone, and its active metabolite, DA-7157, after intravenous and oral administration of DA-7218 and DA-7157 to rats. J Pharm Pharmacol. 2007;59 (7):955–963.Rybak J.M., Roberts K. Tedizolid phosphate: a next-generation oxazolidinone. Infect Dis Ther. 2015;4:1–14.Rybak J.M., Roberts K. Tedizolid phosphate: a next-generation oxazolidinone. Infect Dis Ther. 2015;4:1–14.Locke J.B., Zurenko G.E., Shaw K.J., Bartizal K. Tedizolid for the man¬agement of human infections: in vitro characteristics. Clin Infect Dis. 2014;58 (Suppl 1):S35-S42.Locke J.B., Zurenko G.E., Shaw K.J., Bartizal K. Tedizolid for the man¬agement of human infections: in vitro characteristics. Clin Infect Dis. 2014;58 (Suppl 1):S35-S42.Ferrández O., Urbina O., Grau S. Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections. Drug Des Devel Ther. 2017;11:65–82.Ferrández O., Urbina O., Grau S. Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections. Drug Des Devel Ther. 2017;11:65–82.Colca J.R., McDonald W. G., Waldon D.J. et al. Cross-linking in theliving celllocates the site of action of oxazolidinone antibiotics. J Biol Chem. 2003;278 (24):21972–21979.Colca J.R., McDonald W. G., Waldon D.J. et al. Cross-linking in theliving celllocates the site of action of oxazolidinone antibiotics. J Biol Chem. 2003;278 (24):21972–21979.Kanafani Z.A., Corey G.R. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin Investig Drugs. 2012;21 (4):515–522.Kanafani Z.A., Corey G.R. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin Investig Drugs. 2012;21 (4):515–522.Wilson D.N., Schluenzen F., Harms J.M., Starosta A.L., Connell S.R., Fucini P. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci U S A. 2008;105 (36):13339–13344.Wilson D.N., Schluenzen F., Harms J.M., Starosta A.L., Connell S.R., Fucini P. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci U S A. 2008;105 (36):13339–13344.Leach K.L., Swaney S.M., Colca J.R., McDonald W. G., Blinn J.R., Thomasco L.M. et al. The site of action of oxazoli¬dinone antibiotics inliving bacteria and in human mitochondria. Mol Cell. 2007;26 (3):393–402.Leach K.L., Swaney S.M., Colca J.R., McDonald W. G., Blinn J.R., Thomasco L.M. et al. The site of action of oxazoli¬dinone antibiotics inliving bacteria and in human mitochondria. Mol Cell. 2007;26 (3):393–402.Flanagan S.D., Bien P.A., Munoz K.A., Minassian S.L., Prokocimer P.G. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy. 2014;34 (3):240–250.Flanagan S.D., Bien P.A., Munoz K.A., Minassian S.L., Prokocimer P.G. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy. 2014;34 (3):240–250.Ong V., Flanagan S., Fang E., Dreskin H.J., Locke J.B., Bartizal K. et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos. 2014;42 (8):1275–1284.Ong V., Flanagan S., Fang E., Dreskin H.J., Locke J.B., Bartizal K. et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos. 2014;42 (8):1275–1284.Housman S.T., Pope J.S., Russomanno J. et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother. 2012;56 (5):2627–2634.Housman S.T., Pope J.S., Russomanno J. et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother. 2012;56 (5):2627–2634.Chen R., Shen K., Chang X., Tanaka T., Li L., Hu P. Pharmacokinetics and Safety of Tedizolid after Single and Multiple Intravenous/Oral Sequential Administrations in Healthy Chinese Subjects. Clin Ther. 2016;38 (8):1869–1879.Chen R., Shen K., Chang X., Tanaka T., Li L., Hu P. Pharmacokinetics and Safety of Tedizolid after Single and Multiple Intravenous/Oral Sequential Administrations in Healthy Chinese Subjects. Clin Ther. 2016;38 (8):1869–1879.Sahm D.F., Deane J., Bien P.A., Locke J.B., Zuill D.E., Shaw K.J. еt al. Results of the Surveillance of Tedizolid Activity and Resistance Program: in vitro susceptibility of Gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagnostic Microbiology and Infectious Disease. 2015;81 (2):112–118.Sahm D.F., Deane J., Bien P.A., Locke J.B., Zuill D.E., Shaw K.J. еt al. Results of the Surveillance of Tedizolid Activity and Resistance Program: in vitro susceptibility of Gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagnostic Microbiology and Infectious Disease. 2015;81 (2):112–118.Prokocimer P., Bien P., Surber J., Mehra P., DeAnda C., Bulitta J.B. et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2011;55 (2):583–592.Prokocimer P., Bien P., Surber J., Mehra P., DeAnda C., Bulitta J.B. et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2011;55 (2):583–592.Prokocimer P., De Anda C., Fang E., Mehra P., Das A. Tedizolid phosphate vslinezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309 (6):559–569.Prokocimer P., De Anda C., Fang E., Mehra P., Das A. Tedizolid phosphate vslinezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309 (6):559–569.Moran G.J., Fang E., Corey G.R., Das A.F., De Anda C., Prokocimer P. Tedizolid for 6 days versuslinezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14 (8):696–705.Moran G.J., Fang E., Corey G.R., Das A.F., De Anda C., Prokocimer P. Tedizolid for 6 days versuslinezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14 (8):696–705.Shorr A.F., Lodise T.P., Corey G.R., De Anda C., Fang E., Das A.F. et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015;59 (2):864–871.Shorr A.F., Lodise T.P., Corey G.R., De Anda C., Fang E., Das A.F. et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015;59 (2):864–871.Белькова Ю.А., Рачина С.А., Козлов Р.С., Голуб А.В., Портнягина У.С., Шамаева С.Х. Перспективы включения тедизолида в формуляр российского многопрофильного стационара для лечения осложненных инфекций кожи и мягких тканей. Клин микробиол антимикроб химиотер. 2016;18 (3):174–185.Bel’kova Yu.A., Rachina S.A., Kozlov R.S., Golub A.V., Portnyagina U.S., Shamaeva S.H. Perspectives of tedizolid inclusion in the form of the Russian multi-profile hospital for the treatment of complicated skin and soft tissues infections. Clinical microbiological antimicrobial chemotherapy [Klin. mikrobiol. antimikrob. himioter. 2016;18 (3):174–185.] (In Russ.)

The authors declare that there are no conflicts of interest present.